Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The transcript is about Mondelez's Q4 2016 earnings. The question asks about deals, orders, contracts, projects, customers, sites, or programs. The company is a snack food company. They talk about growth initiatives, white space launches, eCommerce, etc. But do they describe that the individual size of what they land is escalating? For example, they mention launching Milka chocolate in China, repatriation of Nabisco in Japan, entering U.S. chocolate market. But these are new markets, not necessarily larger engagements of the same kind. They talk about eCommerce growing 35% and targeting $1 billion by 2020. But that's overall revenue, not unit size of deals. They mention Kinh Do acquisition and Enjoy Life expansion. But these are acquisitions, not successive engagements of the same kind. The question is about the company's own repeatable business escalating in unit size. For example, if they sell products to retailers, are the orders from retailers getting bigger? There's no such description. They talk about trade spending and promotional intensity, but not about larger orders. They mention price pack architecture, but that's about pricing and pack sizes, not about larger deals. They talk about white space expansions, but that's new categories or geographies, not necessarily larger size of the same kind. The question specifically asks: "does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago?" There is no such statement. They talk about growth in eCommerce, but that's overall revenue, not average order size. They talk about Power Brands growing faster, but that's brand performance, not deal size. They talk about innovation pipeline, but not about larger commitments. They mention that they are seeing green shoots, but not about escalation of unit size. So the answer is NO. The management does not describe that successive engagements are coming in at progressively larger size. They talk about growth, but not about the size of individual deals or contracts increasing.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.